ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

BACKGROUND: The FAST was a factorial trial in first-line treatment of advanced non-small-cell lung cancer (NSCLC), addressing the role of replacing cisplatin with a non-platinum agent. The prognostic and predictive effect of ERCC1/BRCA1 expression and ERCC1/XPD/XRCC1–3 gene polymorphisms on outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiseo, M, Bordi, P, Bortesi, B, Boni, L, Boni, C, Baldini, E, Grossi, F, Recchia, F, Zanelli, F, Fontanini, G, Naldi, N, Campanini, N, Azzoni, C, Bordi, C, Ardizzoni, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669730/
https://www.ncbi.nlm.nih.gov/pubmed/23549037
http://dx.doi.org/10.1038/bjc.2013.127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669730/
https://www.ncbi.nlm.nih.gov/pubmed/23549037
http://dx.doi.org/10.1038/bjc.2013.127

Ejemplares similares